Trials / Completed
CompletedNCT05804656
Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial
A Randomized, Double-blind, Active-controlled, Multi-center Phase 3 Trial to Investigate the Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (actual)
- Sponsor
- CKD Bio Corporation · Industry
- Sex
- All
- Age
- 19 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A Randomized, Double-blind, Active-controlled, Multi-center Phase 3 Trial to Investigate the Efficacy and Safety of CKDB-501A in Subjects with Moderated-to-severe Glabella Lines
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKDB-501A | Intramuscular injection CKDB-501A |
| DRUG | Botox® | Intramuscular injection Botox® |
Timeline
- Start date
- 2023-04-13
- Primary completion
- 2023-08-29
- Completion
- 2023-11-20
- First posted
- 2023-04-07
- Last updated
- 2023-12-12
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05804656. Inclusion in this directory is not an endorsement.